Allergic Asthma, Allergic Conjunctivitis, Allergy, Respiratory Tract Infections, Rhinitis, Allergic
Conditions
Brief summary
Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their mixtures under medial routine at adults with tree- and/or grass-medicated pollinosis.
Detailed description
In this non-interventional study, the change in level of allergen-specific IgE before and after 3 or more years of allergen-specific immunotherapy with Pollinex Quattro in a patient population with tree and/or grass pollen induced pollinosis and/or asthma will be analyzed. In addition, the change in medication usage, asthma status for asthmatic patients after 3, 4 or 5 years of allergen specific immunotherapy will be evaluated. Furthermore, patients will be asked for their change in quality of life after therapy end.
Interventions
DRUGPollinex Quattro with tree- and grass pollen extracts and their mixtures
retrospective analysis of patient records of allergen-specific immunotherapy
Sponsors
Allergy Therapeutics
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients ≥ 18 years * Diagnosis of IgE-mediated rhinitis, conjunctivitis and bronchial asthma on grass and/or tree pollen * completed allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts or their mixtures according to SMPC effective during immunotherapy
Exclusion criteria
* Contraindication according to Summary of Product Characteristics (SMPC) effective during immunotherapy * no additional allergen-specific immunotherapy with another product than Pollinex Quattro
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in allergen specific IgE after allergen-specific immunotherapy | baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy) | Efficacy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in FEV1 (forced expiratory volume at one second; measured in %) after allergen-specific immunotherapy | baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy) | Efficacy |
| Change in lung function resistance (measured in Kpa/l/s) after allergen-specific immunotherapy | baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy) | Efficacy |
| Change in medication usage after allergen-specific immunotherapy | baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy) | Efficacy |
| Assessment of allergic nasal symptoms (rhinorrhea, nasal obstruction) , on a scale 0 -10 (none - severe) after allergen-specific immunotherapy | baseline, post-treatment, at least 3 years of allergen-specific immunotherapy | Efficacy |
| Assessment of allergic lung/bronchial symptoms (shortness of breath, cough), on a scale 0 -10 (none - severe) after allergen-specific immunotherapy | baseline, post-treatment, at least 3 years of allergen-specific immunotherapy | Efficacy |
| Assessment of allergic eye symptoms (itching, tearing, redness, feeling of pressure) , on a scale 0 -10 (none - severe) after allergen-specific immunotherapy | baseline, post-treatment, at least 3 years of allergen-specific immunotherapy | Efficacy |
Countries
Germany
Outcome results
None listed